Buy Actigall

Actigall

Actigall: Ursodeoxycholic Acid Pill Overview

1. Introduction

Actigall is a brand-name medication that contains ursodeoxycholic acid (UDCA) as its sole active ingredient. UDCA belongs to the Digestive Health therapeutic class and is supplied in a 300 mg pill form. In Hong Kong, Actigall is a prescription-only product and is regulated by the Hong Kong Department of Health. The medication is marketed primarily for the dissolution of certain cholesterol gallstones and for the management of cholestatic liver diseases such as primary biliary cholangitis.

2. How Actigall Works in the Body

Ursodeoxycholic acid is a naturally occurring secondary bile acid that is chemically identical to a minor component of human bile. Its therapeutic actions can be summarized as follows:

• Modifies bile composition: UDCA replaces more hydrophobic, potentially toxic bile acids, reducing the cholesterol saturation of bile and making gallstone dissolution possible.
• Cytoprotective effect: It stabilises hepatocyte membranes and reduces the leakage of liver enzymes, which helps protect liver cells from bile-acid-induced injury.
• Choleretic activity: UDCA stimulates bile flow, promoting the clearance of potentially harmful substances from the liver.
• Anti-inflammatory properties: By attenuating immune-mediated damage, UDCA slows the progression of cholestatic liver disorders.

These mechanisms together lower the risk of stone formation and improve liver function in conditions where bile flow is impaired.

3. Conditions Treated by Actigall

Actigall is approved by the Hong Kong regulatory authorities for the following indications:

• Dissolution of radiolucent cholesterol gallstones in patients whose gallbladder is functional and who prefer non-surgical therapy.
• Primary biliary cholangitis (PBC) (formerly primary biliary cirrhosis) to improve liver biochemistry and delay disease progression.

The medication is prescribed for adult patients who meet the clinical criteria for these conditions. It is not indicated for gallstone removal after cholecystectomy or for acute biliary colic.

4. Patient Suitability and Contraindications

Who Should Use Actigall?

• Adults with confirmed cholesterol gallstones that are ≤15 mm in size and who have an intact gallbladder.
• Patients diagnosed with primary biliary cholangitis, particularly those with early-to-mid-stage disease.
• Individuals with normal renal and hepatic function who can swallow pills.

Absolute Contraindications

• Known hypersensitivity to ursodeoxycholic acid or any of the pill’s excipients.
• Complete biliary obstruction (e.g., obstruction of the common bile duct).
• Pregnancy (Category B in Hong Kong) unless the potential benefit outweighs the risk, as safety data are limited.

Relative Contraindications

• Severe hepatic impairment (Child-Pugh C).
• Chronic kidney disease with markedly reduced creatinine clearance.
• Concomitant use of drugs that may cause cholestasis (e.g., certain oral contraceptives) without close monitoring.

Special Populations

• Pregnancy & lactation: Use only if the prescribing clinician deems it necessary; UDCA does cross into breast milk in small amounts.
• Elderly: Dose adjustments may be required for those with reduced renal or hepatic reserve.

5. Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastro-intestinal discomfort (e.g., nausea, abdominal pain) - often mild and transient.
• Diarrhoea - usually dose-related and improves with continued therapy.
• Skin rash - occasional pruritic eruptions that resolve after discontinuation.

Serious Adverse Events

• Hepatotoxicity: Rare elevation of transaminases more than 3-times the upper limit of normal; requires immediate medical review.
• Hypersensitivity reactions: Angio-oedema or severe rash may occur and warrant emergency care.
• Gallstone-related complications: If dissolution is incomplete, residual stones can cause biliary colic or pancreatitis.

Drug Interactions

• Cytochrome P450 enzymes: UDCA is not a strong inhibitor or inducer, but concomitant cholestatic agents (e.g., estrogen-containing oral contraceptives) may reduce its efficacy.
• Antifungal azoles (ketoconazole, fluconazole): May increase UDCA plasma concentrations; periodic liver function testing is advised.
• Warfarin: No direct interaction, but routine INR monitoring is prudent because cholestasis can affect vitamin-K absorption.

Food and Lifestyle Interactions

• Food: Actigall can be taken with or without meals; consistency in timing improves adherence.
• Alcohol: Moderate alcohol intake is permissible, but excessive consumption may worsen liver injury.
• Driving: No impairment has been reported; however, patients experiencing severe abdominal pain should avoid operating heavy machinery.

Note: Patients should disclose all prescription medications, over-the-counter products, herbal supplements, and dietary habits to their healthcare provider before starting Actigall.

6. How to Take Actigall

• Standard dosing: The usual adult regimen begins with 300 mg taken two to three times daily. The total daily dose typically ranges from 600 mg to 1,800 mg, adjusted according to body weight, disease severity, and clinical response.
• Dose titration: For primary biliary cholangitis, clinicians may increase the dose gradually to achieve a target of 15 mg/kg/day (divided doses).
• Renal or hepatic impairment: Lower starting doses (e.g., 300 mg once daily) are advisable, with careful monitoring of liver enzymes and bilirubin.
• Administration: Swallow each pill whole with a glass of water. Do not crush, chew, or split the tablet unless specifically instructed.
• Missed dose: Take the missed pill as soon as remembered if it is within 4 hours of the usual dosing time; otherwise, skip it and resume the regular schedule. Do not double the dose.
• Overdose: Symptoms may include severe diarrhoea, abdominal cramping, and jaundice. Seek emergency medical care; activated charcoal may be considered if presentation is early. There is no specific antidote.
• Discontinuation: Abrupt cessation is generally safe, but clinicians may taper the dose in patients who have been on high-dose therapy for prolonged periods to minimise rebound cholestasis.

7. Monitoring and Follow-Up

• Baseline labs: Liver function tests (ALT, AST, ALP, bilirubin) and serum cholesterol are measured before initiating therapy.
• Follow-up intervals: Repeat liver biochemistry at 4-6 weeks, then every 3-6 months for chronic indications.
• Gallstone response: Ultrasound evaluation after 6-12 months to assess stone dissolution; lack of improvement may prompt surgical referral.
• Pregnancy testing: Women of child-bearing age should have a pregnancy test before starting therapy and be re-tested if a missed period occurs.

8. Storage and Handling

• Keep Actigall pills at room temperature (15-30 °C), protected from excess moisture and direct sunlight.
• Store in the original container with a child-resistant cap.
• Do not use the medication beyond the printed expiration date.
• Unused pills should be discarded according to local pharmacy-take-back programs or the Hong Kong Waste Disposal Ordinance.

9. Medication-Specific Glossary

• Bile acid: A component of bile that aids digestion and absorption of fats; UDCA is a hydrophilic bile acid used therapeutically.
• Cholestasis: A condition where bile flow from the liver is reduced or stopped, leading to accumulation of bile acids in the bloodstream.
• Primary biliary cholangitis: An autoimmune liver disease characterized by gradual destruction of the small bile ducts, leading to cholestasis and fibrosis.
• Gallstone dissolution: The process by which cholesterol gallstones become smaller or disappear after prolonged exposure to agents that alter bile composition, such as UDCA.

10. Medical Disclaimer

This article provides educational information about Actigall and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.